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Background: Pericytes, surrounding the endothelium, fulfill diverse functions that are crucial for vascular homeostasis. The
loss of pericytes is associated with pathologies, such as diabetic retinopathy and Alzheimer’s disease. Thus, there exists a
need for an experimental system that combines pharmacologic manipulation and quantification of pericyte coverage
during sprouting angiogenesis. Here, we describe an in vitro angiogenesis assay that develops lumenized vascular sprouts
composed of endothelial cells enveloped by pericytes, with the additional ability to comparatively screen the effect of
multiple small molecules simultaneously. For automated analysis, we also present an ImageJ plugin tool we developed to
quantify sprout morphology and pericyte coverage.
Methods: Human umbilical vein endothelial cells and human brain vascular pericytes were coated on microcarrier beads
and embedded in fibrin gels in a 96-well plate to form lumenized vascular sprouts. After treatment with pharmacologic
compounds, sprouts were fixed, stained, and imaged via optical z-sections over the area of each well. The maximum
intensity projections of these images were stitched together to form montages of the wells, and those montages were
processed and analyzed.
Results: Vascular sprouts formed within 4–12 days and contained a patent lumen surrounded by a layer of human
endothelial cells and pericytes. Using our workflow and image analysis, pericyte coverage after treatment with various
compounds was successfully quantified.
Conclusions: Here we present a robust in vitro assay using primary human vascular cells that allows researchers to
analyze the effects of multiple compounds on sprouting angiogenesis and pericyte coverage. Our ImageJ plugin offers
automated evaluation across multiple different vascular parameters, such as sprout length, cell density, branch points,
and pericyte coverage.
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Sprouting angiogenesis, the formation of new capillary
branches from pre-existing blood vessels or lymphatic
vessels, is required to build functional vascular networks,
and altered sprouting angiogenesis is involved in many
diseases [1].
Sprouting is induced by activation of endothelial cells
(ECs) via growth factors such as vascular endothelial growth
factor (VEGF), platelet-derived growth factor (PDGF),* Correspondence: jan.eglinger@fmi.ch; lammert@uni-duesseldorf.de
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(HIF)-1α [2]. Activated ECs proliferate, extend into the sur-
rounding tissue [3], and recruit pericytes to attach to the
outer wall of the newly formed vessels [4]. The presence of
pericytes on mature capillaries is required for stabilization
of the endothelium and for regulation of blood flow, as ob-
served in the blood–brain barrier [5, 6]. Pericytes are in
close contact with ECs, as they extend long cytoplasmic
processes across several ECs to encircle the EC-derived vas-
cular tubes. Moreover, they share a basement membrane
and physically interact via numerous contacts such as for
example peg-socket junctions, adhesion plaques, or gap
junctions [7]. Dysfunctional interplay between pericytes andle is distributed under the terms of the Creative Commons Attribution 4.0
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many diseases [8–10], resulting in increased vascular per-
meability and defective vessel maturation, which promote
vessel leakage and inflammation [11]. Cancer cells, for in-
stance, can induce detachment of pericytes from quiescent
vasculature, thereby activating ECs to sprout into the sur-
rounding tissue [12]. Pericyte detachment is also one of the
first pathological hallmarks during diabetic retinopathy. The
disease begins with a thickening of the vascular basement
membrane, followed by a loss of pericytes and an increase
in vascular permeability [13]. Ultimately, neovascularization
causes hemorrhaging and vision loss [14]. On the contrary,
after stroke, pericytes constrict around capillaries to de-
crease blood flow. When these pericytes die, the blood–
brain barrier is disrupted, leading to progressive neuronal
damage [15].
It is hypothesized that pericytes also play a regulatory
role during angiogenesis [11, 16]. Our aim was to de-
velop a method to assess pericyte coverage during
sprouting angiogenesis in a defined human cellular sys-
tem. We modified a sprouting assay that involves ECs
and was previously used in a number of recent publica-
tions [17–19]. Nakatsu et al. described an optimized
angiogenesis assay that leads to vascular sprouts with a
defined lumen. This assay uses fibrin as an extracellular
matrix and is characterized by the formation of vascular
sprouts that harbor patent multi-cellular lumens and a
basement membrane [20]. The sprouts undergo many
critical steps that occur in vivo during angiogenesis. In
order to mimic the in vivo vasculature as accurately as
possible, we have modified their protocol to include hu-
man vascular pericytes [7]. After co-culturing ECs and
pericytes, we verified that sprouts have lumens and that
pericytes attach to the outer wall of vascular sprouts.
Further, we adapted the original method for use in
multi-well plates in order to simultaneously test and
compare multiple treatments under reproducible condi-
tions. Finally, for consistent analysis of sprout morph-
ology and pericyte coverage, we developed an ImageJ
plugin that measures sprout number, length and width,
as well as cell density and pericyte coverage of vascular
sprouts. While similar tools were published for standard-
ized quantification of other angiogenesis assays, such as
“Angiotool” for the quantification of retinal vascular net-
works [21], or “Aqual” for the aortic ring assay [22], no
such standardized tool was previously available for the
bead sprouting assay. Using our optimized analysis
workflow, we tested more than 40 compounds for
their biological effects on sprout morphology and
pericyte coverage.
Here, we describe a standardized procedure of the
bead sprouting assay using human umbilical vein ECs
(HUVECs) and human brain vascular pericytes (HBVPs).
To ensure comparability between experimental repetitionsas well as between different researchers performing the ex-
periments, we developed, using the plugin tool described
below, a standardized automated quantitative analysis of
developing angiogenic sprouts covered with pericytes.
Methods
Cell culture
We used HUVEC (Lonza) up to passage 6 [23], HBVP
(ScienCell) were used up to passage 4, and Detroit-551
human skin fibroblasts (HSF; ATCC) up to passage 20.
For experimental reproducibility, primary cells were
used up to the passage number recommended by the
respective supplier (Lonza, ScienCell, ATCC), as primary
cells lose their identity and responsiveness to angiogenic
stimuli at higher passages [23]. Cells were cultured in
endothelial growth medium (EGM-2; Lonza) at least
24 h prior to starting the sprouting assay.
Sprouting assay
A detailed step-by-step protocol for the sprouting assay is
available in Additional files 1, 2 and 3. The procedure is
based on a sprouting assay reported previously [17–19] that
we extended to include pericytes and be adaptable for cul-
ture in a 96-well plate. In short, dextran-coated Cytodex-3
microcarrier beads (GE Healthcare) were incubated with
HUVEC and HBVP in EGM-2 (Lonza) overnight. We
found an endothelial-to-pericyte ratio of 10:1 to yield opti-
mal pericyte coverage of developing sprouts in accordance
with cell ratios found in tissues varying between 1:1 and
10:1 [7, 24]. Cell-coated beads were then embedded into fi-
brin gels by adding 90 μl beads in PBS (200 beads/ml) with
2.5 mg/ml fibrinogen (Sigma-Aldrich) to 8-μl thrombin
(0.625 U/ml, Sigma-Aldrich) per well in a 96- well plate
(μclear, Greiner Bio-One). The gels were overlaid with hu-
man skin fibroblasts at 1000 cells per well. As previously
published, the cross-talk between ECs and fibroblasts, but
not their direct contact, was shown to be required for the
formation of stable lumenized sprouts [17]. Two hundred
microliters of EGM-2 were subsequently added to each
well. Plates were incubated at 37 °C, 5% CO2, and medium
was changed every other day. After 6 days, when lumenized
sprouts were observed, treatment was started by adding
compounds at the respective concentrations to each well.
Medium and compounds were changed every other day.
The frequency of changing medium and compounds was
chosen based on preliminary experiments that showed a
significant decrease in sprout number and length upon
treatment with the VEGFR inhibitor SU5416.
Phalloidin staining
For assays containing ECs only, fibrin gels were fixed
overnight using 4% paraformaldehyde in PBS. Subse-
quently, gels were washed with PBS, blocked with PBS
containing 0.2% Triton X-100 and 1% BSA, and stained
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(for timing and details, see protocol in Additional file 3).
After three washes (10 min in PBS), the plate containing
the gels was imaged as described below.Immunostaining
Fibrin gels containing EC/pericyte sprouts were fixed
using 4% paraformaldehyde in PBS. Subsequently, gels
were washed with PBS, blocked with PBS containing 3%
Triton X-100 and 1% BSA, incubated with primary anti-
bodies (rabbit polyclonal anti-human Erg-1/2/3, Santa
Cruz; mouse monoclonal anti-human NG2, Abcam) for
at least 60 h, washed with PBS, and stained with second-
ary antibodies (Alexa Fluor 488 donkey anti-mouse IgG,
Life Technologies; Cy3 AffiniPure donkey anti-rabbit
IgG, Jackson ImmunoResearch), as well as Alexa Fluor
647-conjugated phalloidin and DAPI for at least 40 h
(for timing and details, see protocol in Additional file 3).
After three washes (PBS), the plate containing the gels
was imaged as described below.Microscopy
We used an inverted microscope (Zeiss Axio Obser-
ver.Z1) with an automated stage to acquire multi-tile
z-stacks (10-μm intervals) of stained sprouts, using a
Zeiss 10×/NA0.45 objective lens. Both a Zeiss ApoTome
system equipped with Colibri LED light source, as well
as a Zeiss LSM 710 confocal microscope system were
used for imaging. Images were acquired in grid positions
and subsequently stitched using the Grid/Collection
stitching plugin in Fiji [25], resulting in a continuous
image coverage of 70% of each well (3 × 3 mm).Image analysis
Images were analyzed using the Fiji distribution of
ImageJ [26] at version ImageJ 2.0.0-rc-15/1.49k; Java
1.6.0_65 (available as a Life-Line Version from https://
imagej.net/Downloads). We developed a plugin for
sprout analysis that is available from the Angiogenesis
update site within ImageJ and is maintained to work
with the newest version of Fiji (see https://imagej.net/
Following_an_update_site for instructions how to
install the plugin in Fiji). Documentation for our plugin is
available at https://imagej.net/Sprout_Morphology. For
each z-stack acquired, the maximum intensity projection
(MIP) was created (see Additional file 4) and processed
using our plugin. For each 96-well plate, representative
MIPs were used to adjust analysis parameters to improve
image clarity across the entire dataset. Using the provided
script (see Additional file 5), the plugin was then run on
every continuous image to consistently analyze the entire
dataset.Statistical analysis
The results of the sprout analysis were normalized to ei-
ther a PBS control or a DMSO control, depending on
the solvent used to reconstitute each treatment com-
pound (see Additional file 6: Table S1). Within one
assay, the values for repeated conditions in separate
wells were weighted according to the number of beads
in each well. Significant increase or decrease of each
measurement parameter at each treatment condition
was determined using a one-sample t test.
Results
Lumen formation and pericyte coverage in multi-cellular
sprouts
To assess vascular lumen formation within endothelial cell
(EC)-derived vascular sprouts with and without pericytes,
we seeded HUVEC in the presence or absence of HBVP
onto microcarrier beads that subsequently were embedded
into fibrin gels. In Fig. 1, a summary of the experimental
design is shown, which can be performed in either 96-well
plates to screen compounds (Fig. 1a, left side) or in glass-
bottom dishes for staining with various different antibodies
(Fig. 1a, right side). A timeline of the assay and the struc-
ture of a typical vascular sprout derived from human ECs
and pericytes is also shown (Fig. 1b, c).
After an incubation of either 2 (with pericytes) or 4 days
(without pericytes), the first sprouts formed a patent vascu-
lar lumen detectable by bright field transmission light mi-
croscopy (Fig. 2a). After fixation and staining of the F-actin
cytoskeleton by fluorescently labeled phalloidin, a lumen
was also detected in optical cross-sections of confocal
z-stacks (Fig. 2b). Vascular sprouts were composed of mul-
tiple cells connected through VE-cadherin positive junc-
tions and surrounded by a vascular basement membrane
containing laminin (Fig. 2c). Pericytes aligned to the ablum-
inal side of the vascular sprouts (Fig. 2d, e).
Quantitative measurement of sprout morphology and
pericyte coverage
We developed a plugin for ImageJ to measure parameters
of sprout morphology (Fig. 3). For image analysis with our
plugin, MIPs of sprout images were created. The adjust-
ment of analysis parameters was performed on a selected
subset of images representative of the variability within the
whole dataset. We adjusted the measurement parameters
for each of the analysis steps (Fig. 3a–c), including the
number of beads (Fig. 3d–f), number of vascular sprouts
(Fig. 3g–i), total number of nuclei (Fig. 3j–l), and area cov-
ered with pericytes (Fig. 3m–p). The MIPs of whole well im-
ages from 96-well plates or single beads in glass-bottom
dishes were analyzed using the ImageJ plugin we developed.
An example of the produced image-based quantita-
tion is shown in Fig. 4. Starting with the original in-
put image (Fig. 4a), our plugin detects the bead
Fig. 1 Setup and workflow of the EC/pericyte sprouting assay. a Schematic drawing of the assay setup: A 1:10 co-culture of pericytes (red) and endothelial cells are
coated on microcarrier beads (centre) that are then embedded into fibrin gels in each of the inner 60 wells of a 96-well plate (left). Alternatively, cell-coated beads are
embedded into fibrin gels in a glass-bottom culture dish (right). The fibrin gels are subsequently covered with a layer of fibroblast cells (left), which can also be placed onto
filters (right) to facilitate removal and subsequent staining. Developing sprouts are cultured in growth medium containing the desired treatment, and they can be imaged
using an inverted microscope. b Timeline of the assay procedure: after coating ECs or ECs/pericytes on microcarrier beads and embedding them in fibrin gels, sprouts
are grown for up to 6 days, optionally supplied with 10-μM vanadate to accelerate sprout growth; after removal of vanadate by washing with growth medium, treatment
with test compounds or growth factors can be pursued for another 6 days; for image analysis, sprouts are fixed, stained, and imaged using an inverted microscope. c
Schematic representation of a sprout containing ECs (green) and pericytes (red), indicating the quantified sprout parameters
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The intensity of immunostaining against NG2, a
pericyte marker, is used to segment pericyte area in the
image (Fig. 4d). The presence or absence of Erg-1/2/3
staining is used to classify DAPI-positive cell nuclei into
EC and pericyte-derived nuclei (Fig. 4e–g). For length
measurements, the morphological skeleton of the sprouts
is generated (Fig. 4h). The segmentation results are then
used to measure morphological parameters of vascular
sprouts, such as sprout number, length and width, as well
as cell density, the ratio between ECs and pericytes, and
the area of pericyte coverage (Fig. 4m).
Assessment of small molecule modifiers of angiogenesis
identifies specific modulators of pericyte coverage
Using our analysis workflow, we tested more than 40
compounds on their effect on sprout morphology and
pericyte coverage (Additional file 6: Table S1). Weselected in particular those compounds that target path-
ways reported to modulate angiogenesis (e.g., SU5416, a
potent inhibitor of VEGFR-2 [27]; PDGFR inhibitors
[10]; Y27632, a Rho kinase inhibitor [28]; a γ-secretase
inhibitor (Notch signaling) [29]; and modulators of
cAMP signaling [30]) in order to come up with a set of
molecules to be used in a proof-of-concept study. The
results are summarized in Additional file 7: Table S2 and
Additional file 8: Table S3. In sprouts consisting of only
ECs, we identified compounds that significantly de-
creased (11 compounds) or increased (6 compounds)
sprout number (p < 0.05) with at least one of the con-
centrations used (Additional file 7: Table S2). Using a
cut-off value of p < 0.01 (to reduce the chance of finding
false positives), the number of compounds considered
significantly decreasing or increasing sprout number was
6 and 3, respectively. Similarly, sprout length was signifi-
cantly decreased with 12 (with p < 0.01, 5) compounds
Fig. 2 Validation of sprout morphology. a Bright field image of vascular sprouts growing out from an EC-coated bead. b Confocal micrograph of a vascular
sprout stained for F-actin; a patent lumen is seen on an optical cross-section (inset). c Confocal micrographs of a vascular sprout stained for laminin (red),
VE-cadherin (green), and nuclei (DAPI, blue); maximum intensity projection (i), optical cross-section (ii), and optical longitudinal section (iii); 3D configuration
of the optical sections is depicted in simplified illustrations (right). d, e Confocal micrographs of human pericyte/EC-derived vascular sprouts stained for
endothelial nuclei (Erg-1/2/3, white), pericytes (NG2, red), F-actin (phalloidin, green), and nuclei (DAPI, blue); maximum intensity projection showing a bead
with connected sprouts (d), optical longitudinal section of a single sprout (e), showing the vascular lumen (asterisks), EC nuclei (arrowheads), and pericyte
nuclei (block arrows). Scale bars, a 200 μm; b, c 10 μm; d 200 μm; e 10 μm
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presence of pericytes, none of the compounds decreased
the number of sprouts significantly with the concentrations
used, and only 3 compounds significantly increased sprout
number (with p < 0.01, 0; Additional file 8: Table S3).
Sprout length was significantly decreased with 8 (with
p < 0.01, 3) compounds and significantly increased with
2 (with p < 0.01, 0) compounds.
For EC-only sprouts, we measured sprout width and
cell density as additional parameters. We found that 8
out of 41 compounds specifically and significantly (p <
0.05) change sprout width and/or cell density without af-
fecting sprout number or length (Additional file 7: Table
S2). Similarly, we found that 12 out of 42 compounds
specifically changed pericyte coverage in human EC/
pericyte-derived vascular sprouts (Additional file 8:
Table S3).Discussion
The bead sprouting angiogenesis assay in its original
form as described by Nakatsu et al. has been used in a
number of publications to test the specific effects of
agents (e.g., siRNAs, antibodies, chemical inhibitors) on
angiogenesis, and to complement results from in vivo
experiments [31–34]. However, until now, this assay has
not included the important influence of pericytes on vas-
cular sprout formation. We believe that the presented
assay compares favorably with prior uses of published
assays, since the co-culture of pericytes and ECs better
mimics the in vivo vascular system. In addition, the
three-dimensional bead angiogenic sprouting assay has
been used with other cell types than HUVEC such as
human lung ECs [35] and human lymphatic ECs [36].
The bead sprouting assay experimental design has sev-
eral advantages over many comparable in vitro methods,
Fig. 3 Configuration of the Sprout Analyzer plugin. a Dialog to configure output measurement parameters and to define input configuration, i.e.,
which image channel contains which staining information. b Example image showing a microcarrier bead with vascular sprouts stained for F-actin
using phalloidin-AF488 (green) and nuclei using DAPI (blue). c Example image with EC/pericyte-derived sprouts stained for F-actin using phalloidin-AF488
(green), nuclei using DAPI (blue), EC nuclei using an anti-Erg-1/2/3 antibody (white), and pericytes using an anti-NG2 antibody (red). d Dialog to configure
bead detection; when the preview checkbox is activated, a bead mask image (white) is overlaid onto the image (e and f for the original images in b and c,
respectively). g Dialog to configure sprout detection; when the preview checkbox is activated, a sprout mask image (white) is overlaid onto the image (h, i).
j Dialog to configure nucleus detection; when the preview checkbox is activated, a nucleus mask image (white) is overlaid onto the image (k, l). m Dialog to
configure cell classification; when the preview checkbox is activated, a preview showing ECs (yellow) and pericytes (magenta) is overlaid onto the image (n).
o Dialog to configure pericyte coverage measurement; when the preview checkbox is activated, a pericyte area mask image (white) is overlaid onto the
image (p). For detailed instructions, see protocol in Additional file 3, Additional file 1: Video S1, and Additional file 2: Video S2
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and pericytes. Based on a reproducible 3D environment,
the assay produces multi-cellular lumenized sprouts that
possess an abluminal basement membrane [20].
The assay reproduces the cellular mechanisms neces-
sary to form lumenized tubes, in contrast to assays that
focus solely on EC migration [37]. The new ImageJplugin allows for straightforward quantification of peri-
cyte coverage in addition to sprout morphology (see
Additional file 2: Video S2). Future applications of this
assay will benefit from the detailed quantitative analysis
provided by our toolkit. Admittedly, a limitation of the
assay is the absence of blood flow. However, methods
providing a blood flow require a more complex setup,
Fig. 4 Automated multi-parametric image analysis of sprouting angiogenesis with pericytes. a Confocal micrograph (maximum intensity
projection) showing a bead with sprouts stained for F-actin (green), nuclei (blue), endothelial nuclei (white), and pericytes (red). b–d Result
images showing segmentation results (white): segmented bead (b), total sprout area (c) and pericyte area (d). e Cell classification result
showing endothelial nuclei (yellow) and pericyte nuclei (magenta). f–g Result images from the cell classification showing EC nuclei (f) and
pericyte nuclei (g). h Sprout skeleton for length measurements. i–l Magnified details of the marked region in (a, f–h). m Result table
shown after running our plugin on the example image shown in a. Scale bars, a–h 200 μm; i–l 100 μm
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of assays highlighting their respective features is shown
in Additional file 9: Table S4.
With the addition of pericytes, this sprouting angio-
genesis assay is useful to measure effects of different
compounds on pericyte coverage. In our assay, we often
observed vascular sprouts with leading ECs and pericytes
in close vicinity to the endothelium, covering the ablum-
inal side of sprouts with long cellular protrusions
(Fig. 4i–l). The observed sprout morphology is charac-
teristic of pericyte-covered sprouting capillaries in vivo
[6, 7, 10].
Within our test compounds, the number of compounds
that decreased sprout number and length was higher than
those that increased these two parameters. On an
evolutionary-optimized cellular mechanism like angiogen-
esis, it is not surprising to find more inhibiting thanactivating factors. In addition, we observed that the pres-
ence of pericytes on the vessel walls stabilized vascular
sprouts; in the EC/pericyte sprouts, fewer compounds
were able to decrease sprout number, although they were
used at the same concentrations in both experiments.
It should be noted that our sprouting assay, while recap-
itulating the in vivo morphology of pericyte-wrapped
sprouts, suffers from the natural biological variability
present in primary human cells. A careful analysis of its
statistical power should therefore be performed when de-
signing larger studies using this assay to draw meaningful
conclusions. Our proof-of-concept study is limited by its
small sample size, since no robotic platform for
high-throughput screening was used. However, when
comparing groups of compounds with shared properties,
we observed similar behaviors. For example, we observed
that compounds regulating intracellular cyclic adenosine
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A (i.e., 6-Bnz, Forskolin, IBMX, Sp-cAMPS) tended to in-
crease sprout width in our assay (see Additional file 7: Table
S2). In addition, the assay setup also allows measuring the
number of branch points per sprout, in particular when
sprouts are given enough time to form branched networks
and a larger sample size is used. Therefore, we also added
an option to measure the number of branch points in our
plugin (Additional file 10: Figure S1), based on the “Analyze
Skeleton” plugin included in Fiji [38].
The ImageJ plugin we developed provides a comprehen-
sive quantification of morphological parameters in vascular
sprouts. By providing an analysis specific to the bead
sprouting assay, it helps researchers using this assay to get
useful measurements, while still offering flexibility in the
choice of parameters as well as the possibility of adapta-
tions, as its source code is fully available.
Conclusions
Our methodology allows for quantitative assessment of
morphology and pericyte coverage in vascular sprouts de-
veloped from human endothelial cells and human peri-
cytes in vitro. We were also able to observe some of the
expected effects of anti-angiogenic substances, such as
those of VEGF and PDGF receptor inhibitors. The in vitro
bead sprouting angiogenesis assay with pericytes therefore
represents a novel, helpful addition to various in vivo ex-
periments. Our plugin for ImageJ allows to quantify the
results of this assay and is a novel and freely available
quantification tool in the field of digital pathology.
Additional files
Additional file 1: Movie introducing the bead sprouting assay and our
software analysis. (MOV 22013 kb)
Additional file 2: Movie demonstrating the analysis of human EC/
pericyte-derived vascular sprouts. (MOV 4946 kb)
Additional file 3: Step-by-step protocol for the pericyte sprouting assay.
This protocol contains several options of performing the bead sprouting
assay, e.g., with or without pericytes, in a glass-bottom dish or a 96-well
plate format, and with different stainings. (DOCX 132 kb)
Additional file 4: ImageJ macro to create maximum intensity
projections. ImageJ macro (ijm) format; open the file using ImageJ, e.g.,
by dragging onto the ImageJ main window. (IJM 1 kb)
Additional file 5: ImageJ macro to process image folders. ImageJ
macro (ijm) format; open the file using ImageJ, e.g., by dragging onto the
ImageJ main window. (IJM 1 kb)
Additional file 6: Table S1. List of compounds and concentrations
used. The compounds were used at two concentrations, indicated in the
columns 10 × IC50 and 100 × IC50, respectively. The values were chosen
according to published values for the half maximal inhibitory
concentrations of the inhibitors with respect to their target molecules
in vitro or in accordance with literature using the respective compounds
in a similar assay setup. Literature references for each compound are
listed in the reference column. (DOCX 193 kb)
Additional file 7: Table S2. Results of a pilot screen for EC-derived vascular
sprouts. Changes considered significant with a cut-off p value of p< 0.05
(two-sided one-sample t test compared to solvent control) are colored in red
and green to indicate decrease and increase compared to controls, respectively.
N= 3 assays with 8 wells per compound each. (PDF 66 kb)Additional file 8: Table S3. Results of a pilot screen for EC/pericyte-
derived vascular sprouts. Changes considered significant with a cut-off
p value of p < 0.05 (two-sided one-sample t test compared to solvent
control) are colored in red and green to indicate decrease and increase
compared to controls, respectively. N = 3 assays with 8 wells per
compound each. (PDF 67 kb)
Additional file 9: Table S4. Comparison of in vitro and ex vivo assays.
Comparison of in vitro and ex vivo assays to study sprouting angiogenesis, EC
migration, and pericyte coverage. The method presented here is highlighted
in green. Symbols used are the following: +, possible/present; −, not possible/
not present; n.s., not shown. (DOCX 148 kb)
Additional file 10: Figure S1. Quantification of branching level. (a)
Confocal micrograph (maximum intensity projection) of a sprouting
vascular plexus growing from four microcarrier beads, stained for F-actin
(green) and nuclei (red). (b) Result image showing bead (dark grey) and
sprout (light grey) segmentation. (c) Result image showing the sprout
skeletons; branch points have been highlighted in red. (d) The option to
measure branching level (red box) is available in the configuration dialog.
(e) Result table reporting the average number of branch points per
sprout (avg n(branch points), red box). (PNG 375 kb)
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